Yasuaki Arai

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda et al. · Gut · 2019 · 686 citations · Full text

CT-guided needle biopsy of lung lesions: A survey of severe complication based on 9783 biopsies in Japan

Noriyuki Tomiyama, Yoshifumi Yasuhara, Yasuo Nakajima et al. · European Journal of Radiology · 2006 · 487 citations

Ct-guided Needle Biopsy, Medical Imaging, Advanced Lung Disease +12

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 303 citations

Hepatology, Medicine, Clinical Trials +10

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Masatoshi Kudo, Ann‐Lii Cheng, Joong‐Won Park et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 189 citations

Hepatology, Medicine, Transcatheter Arterial Chemoembolisation +9

[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].

Hirokazu Watanabe, Morihito Okada, Yasushi Kaji et al. · PubMed · 2009 · 163 citations

Surgical Oncology, Recist Guideline, Updated Contents +15